CVKD vs. SAVA, SPRO, HLVX, BMEA, ANEB, VIRI, LIMN, SKYE, CNTB, and COYA
Should you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Cassava Sciences (SAVA), Spero Therapeutics (SPRO), HilleVax (HLVX), Biomea Fusion (BMEA), Anebulo Pharmaceuticals (ANEB), Virios Therapeutics (VIRI), Liminatus Pharma (LIMN), Skye Bioscience (SKYE), Connect Biopharma (CNTB), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical products" industry.
Cadrenal Therapeutics vs. Its Competitors
Cassava Sciences (NASDAQ:SAVA) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for Cassava Sciences. Cadrenal Therapeutics' average media sentiment score of 1.13 beat Cassava Sciences' score of 1.02 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.
Cassava Sciences' return on equity of -66.16% beat Cadrenal Therapeutics' return on equity.
Cassava Sciences has a beta of -2.05, meaning that its stock price is 305% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.
38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 2.4% of Cassava Sciences shares are owned by company insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.
Cassava Sciences currently has a consensus target price of $2.00, suggesting a potential downside of 9.09%. Cadrenal Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 156.41%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Cassava Sciences.
Summary
Cadrenal Therapeutics beats Cassava Sciences on 8 of the 13 factors compared between the two stocks.
Get Cadrenal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cadrenal Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CVKD) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access